Development of new diabetes drug halted by maker

July 10, 2013
Development of new diabetes drug halted by maker
Failure of aleglitazar might affect FDA deliberations on whether to ease restrictions on similar drug Avandia.

(HealthDay)—The development of what might have become a significant diabetes drug has been halted by its maker amid concerns that the medication raises the risk for fractures, kidney problems and heart failure in those taking it.

Roche reported Wednesday that it would shut down a late-stage clinical trial of the drug aleglitazar after a monitoring committee found signs of troubling side effects and a lack of effectiveness in patients with type 2 diabetes who had heart problems. The Swiss also closed all other studies of the drug.

"We are disappointed by this outcome as we hoped that aleglitazar would provide significant benefit for patients with who are at risk of cardiovascular disease," Dr. Hal Barron, chief medical officer at Roche, said in a company statement.

The drug was being tested to see if it could prevent heart attacks and strokes, in addition to lowering .

The failure of aleglitazar might color any decision the U.S. Food and Drug Administration may soon make about the troubled Avandia, which is similar to aleglitazar, The New York Times reported.

In 2010, Avandia's use was severely restricted in the United States because evidence suggested it raised the chances of heart attacks and stroke.

An FDA advisory committee recommended in June, however, that the restrictions on Avandia be eased. Thirteen members of the 26-person panel voted to ease the controls, while seven voted to lift them altogether. No decision on that recommendation has been made yet by the agency, although it often follows the advice of its expert panels.

Meanwhile, critics of Avandia argue that the entire class of drugs is dangerous and Avandia's use should remain tightly controlled, the Times reported.

Roche noted in its statement, however, that aleglitazar did not increase the risk of heart attacks or strokes, which may bolster the argument that Avandia also does not raise cardiovascular risks, the newspaper added.

In the aleglitazar study, more than 7,000 people with diabetes who had also suffered a recent heart attack or the onset or worsening of cardiac pain were involved. The study was supposed to last five years, until the beginning of 2015.

Explore further: US experts review heart attack risk of diabetes drug

More information: For more on thiazolidinediones, the class of drugs to which Avandia belongs, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

Related Stories

US experts review heart attack risk of diabetes drug

June 5, 2013
GlaxoSmithKline's controversial diabetes drug Avandia, restricted in the US and banned in Europe over concerns it raises heart attack risk, is getting a second look this week by US medical experts.

FDA reviewing heart risks of Glaxo diabetes pill

April 12, 2013
(AP)—The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster diabetes drug Avandia.

US panel wants changes to Avandia safety measures (Update)

June 6, 2013
US government health experts are recommending changes to safety restrictions on former blockbuster diabetes pill Avandia, in light of a new analysis suggesting that the drug may not increase the risk of heart attack as previously ...

FDA weighs lifting safety restrictions on Avandia (Update 2)

June 3, 2013
A former blockbuster diabetes pill that was subjected to major safety restrictions in 2010 may be less risky than once thought, according to the latest analysis of the much-debated GlaxoSmithKline drug Avandia.

US panel backs novel diabetes pill from J&J (Update)

January 10, 2013
A panel of U.S. health experts ruled Thursday that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked over the long term.

US OKs first-of-its-kind diabetes drug (Update)

March 29, 2013
The U.S. Food and Drug Administration on Friday approved a first-of-its-kind diabetes drug from Johnson & Johnson that uses a new method to lower blood sugar—flushing it out in patients' urine.

Recommended for you

In most surgery patients, length of opioid prescription, number of refills spell highest risk for misuse

January 17, 2018
The possible link between physicians' opioid prescription patterns and subsequent abuse has occupied the attention of a nation in the throes of an opioid crisis looking for ways to stem what experts have dubbed an epidemic. ...

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.